Core Insights - Aclarion, Inc. has received a Notice of Allowance for its 24th US patent, expanding its ability to use Magnetic Resonance Spectroscopy (MRS) to identify propionic acid (PA) throughout the body, which may indicate potential sources of infection and pain [1][6][2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing MRS, proprietary signal processing techniques, and augmented intelligence algorithms to optimize clinical treatments [4] - The company's Nociscan platform is the first evidence-supported SaaS solution designed to help physicians differentiate between painful and non-painful discs in the lumbar spine [4] Patent and Technology Development - The new patent allows Aclarion to measure propionic acid as a biomarker for identifying potential infections and pain beyond just discogenic low back pain [6][2] - MRS is a capability of MRI scanners that provides spectral data on various chemical biomarkers, but traditional MRS post-processing can be challenging; Aclarion's patents address these challenges, enhancing the reliability and quality of spectral data [2][6] Implications of the Patent - The patent's implications are significant, as it positions Aclarion to commercialize MRS applications more broadly, potentially impacting the diagnosis and treatment of various conditions associated with propionic acid [2][6]
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body